Michael R. Franklin

2.9k total citations
91 papers, 2.3k citations indexed

About

Michael R. Franklin is a scholar working on Pharmacology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Michael R. Franklin has authored 91 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pharmacology, 44 papers in Molecular Biology and 18 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Michael R. Franklin's work include Pharmacogenetics and Drug Metabolism (50 papers), Drug Transport and Resistance Mechanisms (18 papers) and Drug-Induced Hepatotoxicity and Protection (14 papers). Michael R. Franklin is often cited by papers focused on Pharmacogenetics and Drug Metabolism (50 papers), Drug Transport and Resistance Mechanisms (18 papers) and Drug-Induced Hepatotoxicity and Protection (14 papers). Michael R. Franklin collaborates with scholars based in United States, Papua New Guinea and Switzerland. Michael R. Franklin's co-authors include Ronald W. Estabrook, John G. Lamb, John D. Phillips, James P. Kushner, Parnali Chatterjee, Alfred G. Hildebrandt, Wael M. El‐Sayed, Jeanette C. Roberts, Hector A. Bergonia and Mildred K. Buening and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Hepatology.

In The Last Decade

Michael R. Franklin

89 papers receiving 2.2k citations

Peers

Michael R. Franklin
Véronique Descatoire France
Elizabeth A. Shephard United Kingdom
Raymond Novak United States
Richard M. Philpot United States
Grace Chao Yeh United States
Donald A. Vessey United States
Thomas M. Guenthner United States
Yuji Ishii Japan
Dominick L. Cinti United States
Maria Almira Correia United States
Véronique Descatoire France
Michael R. Franklin
Citations per year, relative to Michael R. Franklin Michael R. Franklin (= 1×) peers Véronique Descatoire

Countries citing papers authored by Michael R. Franklin

Since Specialization
Citations

This map shows the geographic impact of Michael R. Franklin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Franklin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Franklin more than expected).

Fields of papers citing papers by Michael R. Franklin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Franklin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Franklin. The network helps show where Michael R. Franklin may publish in the future.

Co-authorship network of co-authors of Michael R. Franklin

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Franklin. A scholar is included among the top collaborators of Michael R. Franklin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Franklin. Michael R. Franklin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pond, Christopher D., et al.. (2016). Traditional Preparations and Methanol Extracts of Medicinal Plants from Papua New Guinea Exhibit Similar Cytochrome P450 Inhibition. Evidence-based Complementary and Alternative Medicine. 2016(1). 7869710–7869710. 15 indexed citations
2.
Bergonia, Hector A., Michael R. Franklin, James P. Kushner, & John D. Phillips. (2015). A method for determining δ-aminolevulinic acid synthase activity in homogenized cells and tissues. Clinical Biochemistry. 48(12). 788–795. 12 indexed citations
3.
Franklin, Michael R., et al.. (2012). Major differences among chemopreventive organoselenocompounds in the sustained elevation of cytoprotective genes. Journal of Biochemical and Molecular Toxicology. 26(9). 344–353. 3 indexed citations
4.
5.
Haley, Shannon, John G. Lamb, Michael R. Franklin, Jonathan E. Constance, & M. Denise Dearing. (2008). “Pharm‐Ecology” of Diet Shifting: Biotransformation of Plant Secondary Compounds in Creosote (Larrea tridentata) by a Woodrat Herbivore,Neotoma lepida. Physiological and Biochemical Zoology. 81(5). 584–593. 20 indexed citations
6.
El‐Sayed, Wael M., Tarek Aboul‐Fadl, John G. Lamb, Jeanette C. Roberts, & Michael R. Franklin. (2006). Effect of selenium-containing compounds on hepatic chemoprotective enzymes in mice. Toxicology. 220(2-3). 179–188. 53 indexed citations
7.
El‐Sayed, Wael M. & Michael R. Franklin. (2006). Hepatic chemoprotective enzyme responses to 2‐substituted selenazolidine‐4(R)‐carboxylic acids. Journal of Biochemical and Molecular Toxicology. 20(6). 292–301. 3 indexed citations
8.
El‐Sayed, Wael M., et al.. (2006). The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 627(2). 136–145. 11 indexed citations
9.
El‐Sayed, Wael M., Tarek Aboul‐Fadl, Jeanette C. Roberts, John G. Lamb, & Michael R. Franklin. (2006). Murine hepatoma (Hepa1c1c7) cells: A responsive in vitro system for chemoprotective enzyme induction by organoselenium compounds. Toxicology in Vitro. 21(1). 157–164. 15 indexed citations
10.
Chatterjee, Parnali & Michael R. Franklin. (2003). HUMAN CYTOCHROME P450 INHIBITION AND METABOLIC-INTERMEDIATE COMPLEX FORMATION BY GOLDENSEAL EXTRACT AND ITS METHYLENEDIOXYPHENYL COMPONENTS. Drug Metabolism and Disposition. 31(11). 1391–1397. 122 indexed citations
11.
Franklin, Michael R.. (2002). Modulation of Phase II Drug Metabolizing Enzyme Activities by Nheterocycles. Current Drug Metabolism. 3(6). 599–607.
12.
Franklin, Michael R., John D. Phillips, & James P. Kushner. (2002). Uroporphyria in the uroporphyrinogen decarboxylase-deficient mouse: Interplay with siderosis and polychlorinated biphenyl exposure. Hepatology. 36(4). 805–811. 11 indexed citations
13.
Franklin, Michael R., John D. Phillips, Karen Miller, et al.. (2000). Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. Journal of Laboratory and Clinical Medicine. 136(6). 482–488. 25 indexed citations
14.
Slawson, Matthew H., Michael R. Franklin, & David E. Moody. (1996). Correlations of the induction of microsomal epoxide hydrolase activity with phase II drug conjugating enzyme activities in rat liver. Toxicology Letters. 85(1). 29–34. 10 indexed citations
15.
Lamb, John G., et al.. (1996). Drug metabolizing enzyme induction by benzoquinolines, acridine, and quinacrine; Tricyclic aromatic molecules containing a single heterocyclic nitrogen. Journal of Biochemical Toxicology. 11(6). 297–303. 22 indexed citations
16.
17.
Manning, Bradford W. & Michael R. Franklin. (1990). Induction of rat UDP-glucuronosyltransferase and glutathione S-transferase activities by -S,R- without induction of cytochrome P-450. Toxicology. 65(1-2). 149–159. 18 indexed citations
18.
Franklin, Michael R. & Bryan S. Finkle. (1985). Effect of Murine Gamma-Interferon on the Mouse Liver and Its Drug-Metabolizing Enzymes: Comparison with Human Hybrid Alpha-Interferon. Journal of Interferon Research. 5(2). 265–272. 22 indexed citations
19.
20.
Franklin, Michael R.. (1972). The Incomplete Conversion of Hepatic Cytochrome P-450 to P-420 by Mercurials. Molecular Pharmacology. 8(6). 711–721. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique Descatoire Breakdown of academic impact, for papers by Elizabeth A. Shephard Breakdown of academic impact, for papers by Raymond Novak Breakdown of academic impact, for papers by Richard M. Philpot Breakdown of academic impact, for papers by Grace Chao Yeh Breakdown of academic impact, for papers by Donald A. Vessey Breakdown of academic impact, for papers by Thomas M. Guenthner Breakdown of academic impact, for papers by Yuji Ishii Breakdown of academic impact, for papers by Dominick L. Cinti Breakdown of academic impact, for papers by Maria Almira Correia
Rankless by CCL
2026